Swedish Orphan Biovitrum AB (publ) (STO:SOBI)
Sweden · Delayed Price · Currency is SEK 457.40
-1.00 (-0.22%)
Jul 24, 2026, 5:29 PM CET
STO:SOBI Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 30,623 | 28,238 | 26,027 | 22,123 | 18,790 | 15,529 | |
Revenue Growth (YoY) | 13.54% | 8.49% | 17.65% | 17.74% | 21.00% | 1.76% |
Cost of Revenue | 6,813 | 6,252 | 5,785 | 4,995 | 4,776 | 3,484 |
Gross Profit | 23,810 | 21,986 | 20,242 | 17,128 | 14,014 | 12,045 |
Selling, General & Admin | 18,165 | 17,756 | 11,085 | 10,161 | 7,847 | 6,294 |
Research & Development | 3,724 | 3,317 | 3,538 | 2,796 | 2,354 | 1,994 |
Other Operating Expenses | -70 | 46 | -7 | 106 | 1 | 24 |
Total Operating Expenses | 21,819 | 21,119 | 14,616 | 13,063 | 10,202 | 8,312 |
Operating Income | 1,995 | 867 | 5,625 | 4,066 | 3,813 | 3,733 |
Interest Income | - | 42 | 86 | 50 | 5 | 16 |
Interest Expense | - | -873 | -1,305 | -1,162 | -497 | -454 |
Other Non-Operating Income (Expense) | -730 | -834 | -1,219 | -1,112 | -492 | -438 |
Total Non-Operating Income (Expense) | -730 | -1,665 | -2,438 | -2,224 | -984 | -876 |
Pretax Income | 1,238 | 34 | 4,407 | 2,954 | 3,321 | 3,295 |
Provision for Income Taxes | -145 | -442 | 528 | 546 | 683 | 616 |
Net Income | 1,383 | 476 | 3,879 | 2,409 | 2,638 | 2,679 |
Minority Interest in Earnings | 1 | -2 | -6 | - | - | - |
Net Income to Common | 1,382 | 478 | 3,885 | 2,409 | 2,638 | 2,679 |
Net Income Growth | -68.39% | -87.70% | 61.27% | -8.68% | -1.53% | -17.44% |
Shares Outstanding (Basic) | 345 | 344 | 342 | 323 | 309 | 295 |
Shares Outstanding (Diluted) | 349 | 348 | 346 | 326 | 312 | 297 |
Shares Change (YoY) | 0.57% | 0.59% | 6.01% | 4.32% | 5.27% | -0.28% |
EPS (Basic) | 3.97 | 1.39 | 11.37 | 7.47 | 8.52 | 9.08 |
EPS (Diluted) | 3.93 | 1.37 | 11.24 | 7.39 | 8.44 | 9.03 |
EPS Growth | -68.78% | -87.81% | 52.10% | -12.44% | -6.53% | -17.16% |
Free Cash Flow | 7,749 | 8,426 | 7,133 | 3,597 | 4,504 | 5,423 |
Free Cash Flow Growth | 18.13% | 18.13% | 98.30% | -20.14% | -16.95% | 11.01% |
Free Cash Flow Per Share | 22.20 | 24.24 | 20.64 | 11.03 | 14.41 | 18.27 |
Gross Margin | 77.75% | 77.86% | 77.77% | 77.42% | 74.58% | 77.56% |
Operating Margin | 6.51% | 3.07% | 21.61% | 18.38% | 20.29% | 24.04% |
Profit Margin | 4.52% | 1.69% | 14.90% | 10.89% | 14.04% | 17.25% |
FCF Margin | 25.30% | 29.84% | 27.41% | 16.26% | 23.97% | 34.92% |
EBITDA | 12,302 | 10,963 | 9,304 | 7,266 | 6,232 | 5,739 |
EBITDA Margin | 40.17% | 38.82% | 35.75% | 32.84% | 33.17% | 36.96% |
EBIT | 1,995 | 867 | 5,625 | 4,066 | 3,813 | 3,733 |
EBIT Margin | 6.51% | 3.07% | 21.61% | 18.38% | 20.29% | 24.04% |
Effective Tax Rate | -11.71% | -1300.00% | 11.98% | 18.48% | 20.57% | 18.70% |